Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.

Guo C, Sharp A, Gurel B, Crespo M, Figueiredo I, Jain S, Vogl U, Rekowski J, Rouhifard M, Gallagher L, Yuan W, Carreira S, Chandran K, Paschalis A, Colombo I, Stathis A, Bertan C, Seed G, Goodall J, Raynaud F, Ruddle R, Swales KE, Malia J, Bogdan D, Tiu C, Caldwell R, Aversa C, Ferreira A, Neeb A, Tunariu N, Westaby D, Carmichael J, Fenor de la Maza MD, Yap C, Matthews R, Badham H, Prout T, Turner A, Parmar M, Tovey H, Riisnaes R, Flohr P, Gil J, Waugh D, Decordova S, Schlag A, Calì B, Alimonti A, de Bono JS

Open source

DOI: 10.1038/s41586-023-06696-z
Published: 2023 Nov
Container: Nature
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41586-023-06696-z,
  title = {Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.},
  author = {Guo C and Sharp A and Gurel B and Crespo M and Figueiredo I and Jain S and Vogl U and Rekowski J and Rouhifard M and Gallagher L and Yuan W and Carreira S and Chandran K and Paschalis A and Colombo I and Stathis A and Bertan C and Seed G and Goodall J and Raynaud F and Ruddle R and Swales KE and Malia J and Bogdan D and Tiu C and Caldwell R and Aversa C and Ferreira A and Neeb A and Tunariu N and Westaby D and Carmichael J and Fenor de la Maza MD and Yap C and Matthews R and Badham H and Prout T and Turner A and Parmar M and Tovey H and Riisnaes R and Flohr P and Gil J and Waugh D and Decordova S and Schlag A and Calì B and Alimonti A and de Bono JS},
  year = {2023},
  journal = {Nature},
  doi = {10.1038/s41586-023-06696-z},
  url = {https://doi.org/10.1038/s41586-023-06696-z}
}

RIS

TY  - JOUR
TI  - Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
AU  - Guo C
AU  - Sharp A
AU  - Gurel B
AU  - Crespo M
AU  - Figueiredo I
AU  - Jain S
AU  - Vogl U
AU  - Rekowski J
AU  - Rouhifard M
AU  - Gallagher L
AU  - Yuan W
AU  - Carreira S
AU  - Chandran K
AU  - Paschalis A
AU  - Colombo I
AU  - Stathis A
AU  - Bertan C
AU  - Seed G
AU  - Goodall J
AU  - Raynaud F
AU  - Ruddle R
AU  - Swales KE
AU  - Malia J
AU  - Bogdan D
AU  - Tiu C
AU  - Caldwell R
AU  - Aversa C
AU  - Ferreira A
AU  - Neeb A
AU  - Tunariu N
AU  - Westaby D
AU  - Carmichael J
AU  - Fenor de la Maza MD
AU  - Yap C
AU  - Matthews R
AU  - Badham H
AU  - Prout T
AU  - Turner A
AU  - Parmar M
AU  - Tovey H
AU  - Riisnaes R
AU  - Flohr P
AU  - Gil J
AU  - Waugh D
AU  - Decordova S
AU  - Schlag A
AU  - Calì B
AU  - Alimonti A
AU  - de Bono JS
PY  - 2023
JO  - Nature
DO  - 10.1038/s41586-023-06696-z
UR  - https://doi.org/10.1038/s41586-023-06696-z
ER  -

APA

C, G., A, S., B, G., M, C., I, F., S, J., U, V., J, R., M, R., L, G., W, Y., S, C., K, C., A, P., I, C., A, S., C, B., G, S., J, G., F, R., R, R., KE, S., J, M., D, B., C, T., R, C., C, A., A, F., A, N., N, T., D, W., J, C., MD, F. D. L. M., C, Y., R, M., H, B., T, P., A, T., M, P., H, T., R, R., P, F., J, G., D, W., S, D., A, S., B, C., A, A., & JS, D. B. (2023). Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.. Nature. https://doi.org/10.1038/s41586-023-06696-z

Source records

pubmed · retrieved 2026-09-26T21:07:33.111Z